Advanced search

Filters

Country

All countries

North America

South America

Europe

Africa

Middle East

Asia

Oceania

Central America

Select all

Capitalization

Sector

All sectors

  Energy

  Basic Materials

  Industrials

  Consumer Cyclicals

  Consumer Non-Cyclicals

  Financials

  Healthcare

  Technology

  Utilities

  Real Estate

  Institutions, Associations & Organizations

  Government Activity

  Academic & Educational Services

Select all

Add a keyword

Announcement Date

Since

Until

1105 Results

Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Equinor : Accounts represented on the AGM
PU
FDA Grants Priority Review to Merck’s Application for KEYTRUDA® (pembrolizumab) Plus Chemotherapy as First-Line Treatment of Patients With Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma
BU
Transcript : Appen Limited - Shareholder/Analyst Call
Ebix : Regulation FD Presentation - Form 8-K
PU
Transcript : Portillo's Inc., Q1 2024 Earnings Call, May 07, 2024
Transcript : Jazz Pharmaceuticals plc, Q1 2024 Earnings Call, May 01, 2024
Transcript : Woodside Energy Group Ltd - Shareholder/Analyst Call
Letshego Africa : Notice of Unclaimed Dividends
PU
Transcript : Darden Restaurants, Inc., Q3 2024 Earnings Call, Mar 21, 2024
Merck Provides Update on Phase 3 KEYLYNK-006 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Maintenance LYNPARZA® (olaparib) for Certain Patients With Metastatic Nonsquamous Non-Small Cell Lung Cancer
BU
Transcript : Alpine Immune Sciences, Inc., 2023 Earnings Call, Mar 18, 2024
Qualcomm : 2024 voting results
PU
Transcript : Lancashire Holdings Limited, Q4 2023 Earnings Call, Mar 06, 2024
Heidrick & Struggles Announces Promotions of Partners, Principals, and Senior Client Principals across Executive Search, Heidrick Consulting, and On-Demand Talent Businesses
PR
Transcript : Jazz Pharmaceuticals plc, Q4 2023 Earnings Call, Feb 28, 2024
Transcript : Hargreaves Lansdown plc, H1 2024 Earnings Call, Feb 22, 2024
Transcript : Yum! Brands, Inc., Q4 2023 Earnings Call, Feb 07, 2024
Transcript : Kromek Group plc, H1 2024 Earnings Call, Jan 31, 2024
Health Care Service Corporation, a Mutual Legal Reserve Company entered into an agreement to acquire Medicare Advantage, Cigna Supplemental Benefits and CareAllies Businesses from The Cigna Group (NYSE:CI) for $3.3 billion
CI
2seventy bio Announces New Strategic Path Forward
BU
Advent Technologies Announces Appointment of Naiem Hussain as Chief Financial Officer
BU
Pembina Pipeline : Offering of Subscription Receipts of Pembina Pipeline Corporation - Form 6-K
PU
Transcript : Darden Restaurants, Inc., Q2 2024 Earnings Call, Dec 15, 2023
Merck and Eisai Provide Update on Phase 3 LEAP-001 Trial Evaluating (pembrolizumab) Plus LENVIMA® (lenvatinib) as First-Line Treatment for Patients with Advanced or Recurrent Endometrial Carcinoma
BU
RTX Announces New Lead Independent Director
PR
Transcript : Lancashire Holdings Limited, Q3 2023 Sales/ Trading Statement Call, Nov 09, 2023
Transcript : Alpine Immune Sciences, Inc. - Special Call
PlantX Welcomes Meek's Vegan Pizza to Chicago Foodhall Lineup
CI
Solarvest BioEnergy Inc. Announces Board Changes
CI
European Commission Approves KEYTRUDA® (pembrolizumab) as Adjuvant Treatment for Adults With Non-Small Cell Lung Cancer at High Risk of Recurrence Following Complete Resection and Platinum-Based Chemotherapy
BU
CACI Board Director Gregory G. Johnson Named to NACD Directorship 100
BU
Botswana Insurance : NOTICE TO SHAREHOLDERS - UNCLAIMED DIVIDENDS
PU
Merck and Eisai Provide Update on Two Phase 3 Trials Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Patients With Certain Types of Metastatic Non-Small Cell Lung Cancer
BU
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) as Adjuvant Treatment for Adults with Non-Small Cell Lung Cancer at High Risk of Recurrence Following Complete Resection and Platinum-Based Chemotherapy
BU
Catalent Announces Governance Enhancements and New Initiatives to Drive Value
BU
Merck and Eisai Provide Update on Phase 3 LEAP-010 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Patients With Certain Types of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
BU
Southern BancShares N C : Quarterly Report – June 2023
PU
UK Gilt Yields Fall After Weaker-Than-Expected Retail Sales Data
DJ
Transcript : The Wendy's Company, Q2 2023 Earnings Call, Aug 09, 2023
Union Bankshares : Results of Operations and Financial Condition - Form 8-K
PU
Transcript : Texas Roadhouse, Inc., Q2 2023 Earnings Call, Jul 27, 2023
Tastemaker Acquisition Corp. Announces Board Changes
CI
Tastemaker Acquisition Corp. Announces CEO Changes
CI
Workhorse : STIPULATION OF SETTLEMENT - Form 8-K
PU
Patterson UTI Energy : Transcript of Investor Call - Form 8-K
PU
Transcript : ACADIA Pharmaceuticals Inc. - Special Call
KEYTRUDA® (pembrolizumab) Plus Chemotherapy Significantly Improved Overall Survival Versus Chemotherapy Alone as First-Line Treatment for Unresectable Advanced Pleural Mesothelioma
BU
Transcript : Appen Limited - Shareholder/Analyst Call
KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrates Long-Term, Durable Survival Benefit Versus Sunitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma
BU
Transcript : Seadrill Limited, Q1 2023 Earnings Call, May 23, 2023
No results for this search
  1. Stock Market
  2. Advanced search
  3. Gregory Johnson
  4. News